Medicilon to Complete Pre-Clinical Work on South Korean Anti-Depressant

Medicilon, a Shanghai CRO, has agreed to complete the pre-clinical development of a new anti-depressant developed by SK Biopharmaceuticals of South Korea. Medicilon will prepare the work for both China and US approval of the small molecule, known as SKL-PSY, which is being developed as a treatment of depression and bipolar disorder. More details....
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.